©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 16, 2024; 12(17): 3188-3193
Published online Jun 16, 2024. doi: 10.12998/wjcc.v12.i17.3188
Published online Jun 16, 2024. doi: 10.12998/wjcc.v12.i17.3188
Primary ovarian cancer combined with primary fallopian tube cancer: A case report
Su-Ning Bai, Qi Wu, Li-Yun Song, Department of Gynecology, Hebei General Hospital, Shijiazhuang 050000, Hebei Province, China
Author contributions: Bai SN and Song LY wrote original draft and analyzed the data; Bai SN contributed resources and software; Bai SN and Wu Q completed investigation and final writing, review and editing; and all authors have read and approve the final manuscript.
Informed consent statement: This report was prepared with the written consent of the patient.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Su-Ning Bai, MA, Attending Doctor, Department of Gynecology, Hebei General Hospital, 348 Heping West Road, Xinhua District, Shijiazhuang 050000, Hebei Province, China. 158494897@qq.com
Received: February 2, 2024
Revised: April 9, 2024
Accepted: May 6, 2024
Published online: June 16, 2024
Processing time: 123 Days and 2.4 Hours
Revised: April 9, 2024
Accepted: May 6, 2024
Published online: June 16, 2024
Processing time: 123 Days and 2.4 Hours
Core Tip
Core Tip: Although the prognosis of low grade serous carcinoma of the ovary (LGSOC) is relatively good, over 80% of patients still experience disease recurrence. In most cases, these patients are relatively young and have the potential to receive active treatment and achieve a longer survival period. The treatment methods for LGSOC recurrence include re-tumor reduction surgery, chemotherapy, targeted therapy, hormone therapy and clinical trials. Currently, a large amount of research focuses on gene testing and targeted therapy. I hope that the progress of genome research and targeted therapy can change the therapeutic prospects of LGSOC and bring better therapeutic effects to patients with this disease.